Table 2.
Sensitivity and specificity of new tests for staging.
| Neopterin (nmol/L) | CXCL-13 (pg/mL) | |
|---|---|---|
| Non-stage 1 | 15.57 | 91.21 |
| Sensitivity [IC] | 0.90 [0.73; 0.98] | 0.90 [0.73; 0.98] |
| Specificity [IC] | 0.86 [0.74; 0.94] | 0.79 [0.66; 0.89] |
|
| ||
| Int stage | ||
| Sensitivity [IC] | 0.65 [0.43; 0.84] | 0.52 [0.31; 0.73] |
| Specificity [IC] | 0.94 [0.85; 0.98] | 0.95 [0.87; 0.99] |
|
| ||
| Ad stage 2 | 60.31 | 395.45 |
| Sensitivity [IC] | 0.97 [0.85; 1.00] | 0.90 [0.85; 1.00] |
| Specificity [IC] | 1.00 [0.93; 1.00] | 0.86 [0.93; 1.00] |
The cut-off values established for neopterin and CXCL-13 are expressed in nmol/L and pg/mL, respectively. The sensitivity and specificity values for each cut-off points determined by ROC analysis are shown in the table. The authors defined cut-off values of neopterin and CXCL-13 for non-stage 1 patients, under which patients are considered to be in stage 1 of sleeping sickness.